Urinary Incontinence Treatment Devices Market Size & Share 2024 - 2032

Urinary Incontinence Treatment Devices Market Size

Urinary Incontinence Treatment Devices Market size was valued at around USD 3.1 billion in 2023 and is expected to expand at a CAGR of 8.6% between 2024 and 2032. Factors such as increasing prevalence of urinary incontinence (UI), growing incidence of prostate cancer coupled with rise in target population base for urethral disorders are propelling the market growth over the analysis period.

The rising prevalence of urinary incontinence conditions has led to an increased demand for urinary incontinence treatment devices globally. Factors including the aging population, longer life expectancies, dietary and lifestyle changes, and an increase in obesity and diabetes rates among others are all contributing to the rising global prevalence of UI.  For instance, according to The Epidemiology of Incontinence (EPIC) study, the prevalence of UI is estimated to be 8.7% worldwide. Further, the disease is more prominent in women due to several factors including, menopause, delivery, obesity, and diabetes.
 

Additionally, Asia's older adult female population was found to have the highest prevalence of urine incontinence, at 45.1%. Therefore, the growing incidence of UI among the aging population emphasizes the necessity for urinary incontinence treatment devices in order to enhance the quality of life of affected individuals.
 

Urinary incontinence treatment devices refer to a range of medical devices designed to assist in the management and treatment of urinary incontinence. These devices are intended to help individuals with urinary incontinence regain control over their bladder function or provide support to prevent leakage.
 

Urinary Incontinence Treatment Devices Market Trends

The consistent technological advancements in devices and surgical techniques have fuelled the demand for urinary incontinence treatment devices. Different technologies such as, ultrasound imaging, non-invasive wearable medical devices, and assistive electronic devices among others are supporting the industry growth.
 

• Ongoing research and development efforts have resulted in innovative non-invasive wearable devices for urinary incontinence detection, such as sensor-based systems that enable continuous monitoring and early detection of urinary incontinence episodes. For instance, electronic components and sensors are sewed into underwear to identify urine incontinence and offer automated diaper warning systems. Thus, such advancements can be used to enhance urological conditions diagnosis and treatment.
   
• Additionally, technological advancements in electrical stimulation  device solutions for urology, aid in offering better control in continence care patients. For instance, the development of nerve stimulation devices by utilizing the Axonics modulation technology prevents accidental leakages as the device send a mild electric current to nerves in the lower back or the pelvic muscles that control urination.
   

Urinary Incontinence Treatment Devices Market Analysis

Based on product, the urinary incontinence treatment devices market is categorized into urethral slings, urinary catheters, electrical stimulation devices, artificial urinary sphincters, and other products. The urethral slings segment accounted for majority share and was valued at over USD 1.5 billion revenue in 2023.
 

• The rising demand for minimally invasive procedures globally, is among a key factor contributing to greater adoption of urethral slings in target population. Urethral slings provide a less invasive treatment option for urine incontinence. For instance, sling placement using laparoscopic or robotic techniques involves smaller incisions compared to traditional open surgeries. This reduced invasiveness leads to quicker recovery times, shorter hospital stays, and less postoperative pain, increasing the demand for urethral sling surgeries.
   
• Additionally, urethral slings, especially vaginal slings, particularly mid-urethral slings, have demonstrated notable efficacy in addressing stress urinary incontinence. The robust response of mid-urethral slings to this condition is reflected in high levels of patient satisfaction and substantial cure rates. These positive outcomes underscore the value and effectiveness of urethral slings as a solution for individuals seeking reliable and successful interventions for stress urinary incontinence.

Learn more about the key segments shaping this market

Download Free PDF

Based on incontinence type, the urinary incontinence treatment devices market is segmented into stress, urge, mixed, and other incontinence types. The stress segment held leading revenue share in 2023 and is anticipated to reach USD 3.1 billion by 2032.
 

• The growing prevalence of stress urinary incontinence (SUI) is a significant factor contributing to the market growth. The incidence of stress urine incontinence is generally higher in the elderly population. For instance, according to data reported by National Association for Continence, Stress urinary incontinence is the most prevalent form of incontinence, and it affects around 15 million adult U.S. women. The number of people suffering from SUI is rising as the world's population ages, which is further fueling the demand for associated devices over the analysis timeframe.
   
• Additionally, urinary tract infection (UTI) may exacerbate the symptoms of SUI in women, leading to an increased need for stress incontinence devices. The presence of UTIs can worsen the severity of incontinence and may necessitate the use of devices for effective management and treatment. Therefore, the prevalence of UTIs contributes to the growing demand for incontinence devices globally.
   

Based on category segmentation, the market is categorized into internal incontinence devices and external incontinence devices. The internal incontinence devices segment accounted for majority revenue share and was valued at around USD 2.2 billion revenue in 2023.
 

• Patient preference is a significant factor behind the growing demand for internal incontinence devices, owing to their advanced features. Urethral inserts and pessaries, for instance, offer discreet and comfortable solutions for incontinence management. These devices provide a non-invasive or minimally invasive approach, avoiding the introduction of pharmaceuticals into the system. This convenience factor makes them a preferred option among patients, contributing to the growing demand for advanced internal incontinence devices in the market.
   
• Furthermore, continuous advancements in internal continence devices are geared towards customizing solutions to meet the specific needs of patients. For instance, vaginal sponges offer temporary control by exerting pressure on bladder tissues. These solutions are tailored to address distinct types of incontinence, including stress incontinence or pelvic organ prolapse. This targeted approach reflects the commitment in providing tailored and effective solutions for patients dealing with incontinence conditions.
   

Based on end-use segmentation, the market is categorized into hospitals, clinics, ambulatory surgical centers, and other end-users. The hospitals segment accounted for majority revenue share and was valued at around USD 1.6 billion revenue in 2023.
 

• Hospitals need a wide variety of urinary incontinence treatment devices to treat a range of medical disorders related to urology. The multifaceted nature of urinary incontinence, that may require a combination of diagnostic, therapeutic, and surgical interventions, makes hospital-settings a central hub for the comprehensive management of such conditions.
   
• Additionally, hospitals, being primary centers for the treatment of a diverse range of medical conditions, often encounter a high volume of patients facing illnesses that can lead to urinary incontinence. The demand for these devices is driven by the need to address and manage incontinence stemming from various health conditions, making hospitals a crucial focal point for the acquisition and utilization of urinary incontinence treatment solutions.

North America urinary incontinence treatment devices market accounted for USD 1 billion revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• There is a concerted effort in North America to raise awareness and educate individuals about urinary incontinence, its causes, and available treatment options. For instance. The National Association for Continence, based in the U.S., is dedicated to improving the quality of life of individuals with incontinence. NAFC conducts awareness campaigns that focus on educating both the public and healthcare professionals about the causes, treatment options, and management strategies for urinary incontinence. Such awareness initiatives encourages more people to seek medical attention, thereby, driving the demand for incontinence management products.
   
• Additionally, the regulatory landscape in North America is conducive to healthcare innovation, providing a supportive framework for the development, approval, and commercialization of novel urinary incontinence treatment devices. This favorable regulatory environment significantly contributes to the growth of the market by streamlining the processes involved in incorporating innovative solutions to market.
   

Urinary Incontinence Treatment Devices Market Share

The urinary incontinence treatment devices industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products with improved efficiency and cost-effectiveness is among a key market strategy for urinary incontinence treatment devices manufacturers. Some of the key industry players including Becton, Dickinson and Company, Boston Scientific Corporation, B Braun Melsungen AG, Caldera Medical Inc., and Medtronic plc among others have a substantial presence in the market.
 

Urinary Incontinence Treatment Devices Market Companies

Some of the eminent market participants operating in the urinary incontinence treatment devices industry include:

• Becton, Dickinson and Company
• Boston Scientific Corporation
• B Braun Melsungen AG
• Caldera Medical Inc.
• Coloplast A/S
• ConvaTec Group plc
• Hollister Incorporated
• Medtronic plc
• PROMEDON GmbH
• Teleflex Incorporated
• Zephyr Surgical Implants
   

Urinary Incontinence Treatment Devices Industry News

• In January 2024, Boston Scientific announced an agreement to acquire Axonics, Inc., a medical technology company primarily focused on the development and commercialization of sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction. The acquisition is expected to be highly accretive to Boston Scientific's urology portfolio and business in coming years.
   
• In March 2022, Medtronic announced the first patient implants in the TITAN 2 pivotal study, which evaluate the implantable tibial neuromodulation (TNM) device for the treatment of bladder incontinence. The TNM device aims to reduce the burden on patients and physicians by delivering ongoing neuromodulation therapy without the need for repeat clinic visits. This addition of the device increased the companies product offering in the urinary incontinence care segment.
   

The urinary incontinence treatment devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Urethral slings
  • Male slings
  • Female/vaginal slings
    • Transobturator slings
    • Tension-free vaginal tape slings
    • Mini-slings
• Urinary catheters
  • Indwelling catheters
  • Intermittent catheters
  • External catheters
• Electrical stimulation devices
• Artificial urinary sphincters
• Other products

Market, By Incontinence Type

• Stress
• Urge
• Mixed
• Other incontinence types

Market, By Category

• Internal incontinence devices
• External incontinence devices

Market, By End-use

• Hospitals
• Clinics
• Ambulatory surgical centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa